ArticleJournal of pharmaceutical health care and sciences2025
Risk factors for falls in patients treated with chemotherapy.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fall-related injuries in older adult cancer survivors: a decade of racial disparities.BMC geriatrics · 2026Article
- Assessment of Fall Risk in Oncology Patients: A Scale Development Study.Scandinavian journal of caring sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFalls are a serious concern for hospitalized patients, as they can lead to a decline in quality of life (QOL) and increased nursing care needs. Chemotherapy-induced peripheral neuropathy (CIPN) increases the risk of falls; however, only a few reports have investigated CIPN in conjunction with other factors. This study aimed to identify risk factors for falls in hospitalized patients undergoing chemotherapy.
methodsWe retrospectively analyzed 21,717 hospitalized patients, including 443 who received chemotherapy, at Matsuyama Shimin Hospital between April 2016 and March 2023. Multivariate logistic regression analysis was performed to assess the fall risk in hospitalized patients who received chemotherapy.
resultsAmong 21,717 hospitalized patients, 930 (4.3%) experienced at least one fall. Multivariate logistic regression identified 13 factors, including age, sex, BMI, and mobility assistance. Notably, chemotherapy showed the highest odds ratio among these factors (OR 3.40, 95% CI 2.49-4.65). In the chemotherapy subgroup (n = 443), multivariate analysis identified five factors (body mass index (BMI); decline in judgment, comprehension, and memory; treatment with hypoglycemic drugs; treatment with high-risk CIPN drugs; and lung cancer). The fall rate was significantly higher in patients who received both hypoglycemic drugs and high-risk CIPN drugs (37.5%, 6/16) than in those who received either factor alone (14.1%, 27/192; p < 0.05).
conclusionsChemotherapy was identified as an independent risk factor for falls. Among patients receiving chemotherapy, both hypoglycemic drugs and high-risk CIPN drugs were associated with an increased risk of falls, and the fall rate was significantly higher in those treated with both drugs. Therefore, these patients should be carefully monitored for fall risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.